Skip to main content
Premium Trial:

Request an Annual Quote

Cellzome, GSK Sign $45M Screening Pact

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GlaxoSmithKline will use Cellzome's chemical proteomics platform to identify potential candidates for small-molecule drugs for immunoinflammatory disease.

Under terms of the agreement, GSK will have exclusive access to Cellzome's Episphere technology for epigenetic research on immunoinflammatory disease. As part of the deal, Cellzome will receive from the drug maker a €33 million ($45 million) up-front payment. If the programs under this alliance are successfully developed and commercialized, Cellzome could be eligible for milestone payments of over €475 million.

The firms will work together using the Episphere technology to identify candidates against targets from four different epigenetic target classes. The partners will share responsibility for the programs until candidates are identified, when GSK will take over preclinical and clinical development and commercialization.

The Episphere technology enables researchers to screen and profile inhibitors of epigenetic targets in their native environments, including lysate cells and tissues, said Cellzome.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.